[Clinical study of rokitamycin dry syrup in pediatrics].
A total of 22 patients with acute pediatric infections was treated with rokitamycin (TMS-19-Q, RKM) dry syrup, a new macrolide antibiotic developed by Toyo Jozo Co., Ltd., Ohhito, Japan, to investigate its clinical efficacy. 1. A girl of an age 4 years 2 months (weighing 16.5 kg) was administered orally 10 mg/kg of RKM, and a boy of an age 8 years 7 months (weighing 24.5 kg), 15 mg/kg, and blood concentrations of RKM in these subjects were measured to investigate its absorption and excretion. Blood concentrations of the drug reached a peak of 0.84 microgram/ml in an hour after the administration in the girl, 0.72 microgram/ml in 30 minutes in the boy, with T1/2 of 0.86 and 1.82 hours, respectively. Their 6-hour cumulative urinary recovery rates were 2.79 and 2.13%, respectively. 2. A total of 20 patients was treated with RKM dry syrup. These patients included 3 with acute pharyngitis, one with acute tonsillitis, 4 with hemolytic streptococcal infections, 7 with acute bronchitis, 2 with pneumonia, another 2 with pertussis, and one with Campylobacter enteritis. The treatment was effective in 18 of them with a clinical efficacy of 90.0%. 3. Bacteriological responses to RKM dry syrup were as follows: eradication of pathogens in 5, pathogens decreased in 3, and no changes were observed in 3 of 12 patients from whom pathogens had been isolated prior to the treatment, thus the eradication rate was 45.5% with the exception of 1 patient whose bacteriological response was unknown.(ABSTRACT TRUNCATED AT 250 WORDS)
Minamitani
M
M
Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital.
Hachimori
K
K
Kaneda
K
K
D000284:Administration, Oral; D000293:Adolescent; D001991:Bronchitis / Q000188:drug therapy / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D006801:Humans; D007223:Infant; D007933:Leucomycins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015644:Miocamycin / Q000031:analogs & derivatives*; D010612:Pharyngitis / Q000188:drug therapy / Q000378:metabolism; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000378:metabolism
D007933:Leucomycins; D015644:Miocamycin; C033383:rokitamycin